Teva Pharmaceuticals Announces Promising Mid-Stage Trial Results for Celiac Disease Drug

Israeli pharmaceutical giant Teva announced on Wednesday positive results from its Phase 2a clinical trial for TEV-408, an experimental drug designed to treat celiac disease. The trial involved 50 adults with celiac disease who received a single dose of TEV-408. Following the dose, participants underwent a six-week "gluten challenge," consuming gluten daily to assess the drug's protective effects on the small intestine.

The study met its primary endpoint, demonstrating that TEV-408 significantly prevented gluten-induced damage to the small intestine compared to a placebo, with both statistical and clinical significance. The drug also showed positive impacts on intestinal inflammation markers and digestive symptoms. Teva reported that the drug was well-tolerated, with no new safety concerns identified.

If TEV-408 continues to show positive results in later development stages and gains regulatory approval, it could represent a major breakthrough for celiac disease patients, as there is currently no approved drug treatment, and the standard management is a strict gluten-free diet. Teva also believes TEV-408 has potential applications for treating vitiligo, an autoimmune skin condition, and is planning to advance the drug to a Phase 2b trial for this indication.

The announcement led to a significant increase in Teva's stock price, with shares jumping up to 4% on the Tel Aviv Stock Exchange and in early New York trading. While Teva's stock has experienced a strong upward trend in recent years, rising over 80% in the past year and nearly 300% in the last five years, it remains considerably below its 2015 peak.